Translation

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Summary of Consolidated Financial Results for the Three Months Ended December 31, 2020 (Based on Japanese GAAP)

February 4, 2021

Company name: Fuji Pharma Co., Ltd.
Stock exchange listing: Tokyo
Stock code: 4554 URL http://www.fujipharma.jp
Representative: President & CEO Takayuki Iwai
Inquiries: Corporate Officer,General Manager, Corporate Planning Department Takeshi Sato TEL 03-3556-3344
Scheduled date to file Quarterly Securities Report: February 8, 2021
Scheduled date to commence dividend payments: –
Preparation of supplementary material on quarterly financial results: No
Holding of quarterly financial results meeting: No

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the three months ended December 31, 2020 (from October 1, 2020 to December 31, 2020)

(1) Consolidated operating results (cumulative) Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended December 31, 2020	9,295	3.6	1,698	61.2	1,732	59.6	1,328	78.3
Three months ended December 31, 2019	8,968	(12.7)	1,053	(34.4)	1,085	(29.1)	745	(32.0)

	Earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended December 31, 2020	42.64	–
Three months ended December 31, 2019	23.92	–

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of December 31, 2020	62,913	40,723	64.7
As of September 30, 2020	61,962	39,961	64.5

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended September 30, 2020	–	14.00	–	15.00	29.00
Year ending September 30, 2021	–				
Year ending September 30, 2021 (Forecast)		14.00	–	15.00	29.00

3. Forecast of consolidated financial results for the year ending September 30, 2021 (from October 1, 2020 to September 30, 2021)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending March 31, 2021	17,301	2.3	1,685	(2.9)	1,659	3.0	1,302	318.8	41.78
Full year	34,702	2.7	2,857	(9.0)	2,807	(5.9)	2,100	0.7	67.40

4. Notes

(1) Changes in significant subsidiaries during the three months ended December 31, 2020 (changes in specified subsidiaries resulting in the change in scope of consolidation): No

(2) Application of special accounting methods for preparing quarterly consolidated financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements

Changes in accounting policies due to revisions to accounting standards and other regulations:	No
Changes in accounting policies due to other reasons:	Yes
Changes in accounting estimates:	Yes
Restatement of prior period financial statements:	No

(4) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2020	31,253,800 shares	As of September 30, 2020	31,253,800 shares

Number of treasury shares at the end of the period

As of December 31, 2020	91,988 shares	As of September 30, 2020	95,260 shares

Average number of shares during the period (cumulative from the beginning of the fiscal year)

Three months ended December 31, 2020	31,159,429 shares	Three months ended December 31, 2019	31,153,908 shares

Quarterly consolidated financial statements
Consolidated balance sheets

(Millions of yen)

	As of September 30, 2020	As of December 31, 2020
Assets		
Current assets		
Cash and deposits	12,041	10,163
Notes and accounts receivable - trade	11,700	14,091
Merchandise and finished goods	3,858	3,354
Work in process	2,265	2,109
Raw materials and supplies	4,557	5,381
Accounts receivable - other	8	218
Other	541	594
Allowance for doubtful accounts	(0)	(0)
Total current assets	34,975	35,913
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	5,948	6,070
Machinery, equipment and vehicles, net	3,448	3,608
Land	897	919
Leased assets, net	1,752	1,651
Construction in progress	454	413
Other, net	265	278
Total property, plant and equipment	12,767	12,942
Intangible assets		
Goodwill	1,144	1,109
Other	1,754	1,743
Total intangible assets	2,899	2,852
Investments and other assets		
Investment securities	7,000	6,649
Long-term advance payments	2,308	2,618
Deferred tax assets	1,189	1,089
Other	821	846
Total investments and other assets	11,320	11,204
Total non-current assets	26,987	27,000
Total assets	61,962	62,913

(Millions of yen)

	As of September 30, 2020	As of December 31, 2020
Liabilities		
Current liabilities		
Notes and accounts payable - trade	3,680	5,098
Short-term borrowings	1,000	1,000
Current portion of long-term borrowings	1,640	1,640
Lease obligations	516	511
Income taxes payable	460	427
Provision for bonuses	432	210
Provision for bonuses for directors (and other officers)	6	1
Provision for sales returns	21	14
Other	3,246	2,524
Total current liabilities	11,004	11,428
Non-current liabilities		
Long-term borrowings	7,590	7,180
Lease obligations	1,444	1,348
Retirement benefit liability	1,548	1,599
Other	413	633
Total non-current liabilities	10,996	10,761
Total liabilities	22,001	22,190
Net assets		
Shareholders' equity		
Share capital	3,799	3,799
Capital surplus	5,841	5,841
Retained earnings	30,424	31,285
Treasury shares	(68)	(63)
Total shareholders' equity	39,995	40,861
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(650)	(903)
Foreign currency translation adjustment	600	751
Remeasurements of defined benefit plans	12	11
Total accumulated other comprehensive income	(37)	(141)
Non-controlling interests	2	3
Total net assets	39,961	40,723
Total liabilities and net assets	61,962	62,913

Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)

Consolidated statements of income (cumulative)

(Millions of yen)

	Three months ended December 31, 2019	Three months ended December 31, 2020
Net sales	8,968	9,295
Cost of sales	4,901	5,260
Gross profit	4,067	4,034
Selling, general and administrative expenses	3,013	2,336
Operating profit	1,053	1,698
Non-operating income		
Interest income	0	0
Foreign exchange gains	36	38
Subsidy income	–	4
Commission income	0	0
Compensation income	3	0
Insurance claim income	0	0
Other	2	1
Total non-operating income	44	44
Non-operating expenses		
Interest expenses	10	8
Sales discounts	1	1
Other	0	0
Total non-operating expenses	12	10
Ordinary profit	1,085	1,732
Extraordinary income		
Gain on sales of non-current assets	0	1
Gain on sales of securities	–	152
Total extraordinary income	0	154
Extraordinary losses		
Loss on retirement of non-current assets	0	1
Total extraordinary losses	0	1
Profit before income taxes	1,086	1,885
Income taxes - current	69	393
Income taxes - deferred	271	163
Total income taxes	340	556
Profit	745	1,328
Profit attributable to non-controlling interests	0	0
Profit attributable to owners of parent	745	1,328

Consolidated statements of comprehensive income (cumulative)

(Millions of yen)

	Three months ended December 31, 2019	Three months ended December 31, 2020
Profit	745	1,328
Other comprehensive income		
Valuation difference on available-for-sale securities	285	(253)
Foreign currency translation adjustment	150	150
Remeasurements of defined benefit plans, net of tax	14	(1)
Total other comprehensive income	450	(103)
Comprehensive income	1,196	1,224
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,195	1,224
Comprehensive income attributable to non-controlling interests	0	0